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Response Evaluation Criteria for Solid Tumours (RECIST)
were introduced in 2000 to provide a standardized method
for assessing response to treatments in the clinical trial
setting [1]. The RECIST Working Group has updated
RECIST to version 1.1 [2]. The revised version has
maintained assessment of tumour burden using sum of
the diameters and continues to use uni-dimensional mea-
surements. The response categories are still those of com-
plete response, partial response (30% decrease in sum
from baseline), stable disease and progressive disease (20%
increase in sum from nadir). The revision addressed issues
that had arisen related to the use of the criteria in practice.
Though the RECIST criteria are intended for use in
the clinical trial setting, oncologists increasingly rely on
RECIST based measurements to make clinical manage-
ment and therapeutic decisions in daily clinical practice.
The reasons for this include the clinician’s application
of trial data into routine clinical practice but most
importantly RECIST offers a simple way of measuring
and communicating response assessment. The terms
such as measureable disease, tumour burden, target
lesions, and response categories are now used and
understood universally. RECIST criteria also provide
guidance on technique as well as measuring lesions and
application to assessing sites of disease, eg lymph node
and bones. This allows for a more robust and reproduci-
ble way of gauging response. The limitations of RECIST
are also well known thereby allowing the clinician to
understand the pitfalls in those cases. Therefore the
radiologist has to understand and use “RECIST” in their
daily practice.
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